These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 8146828)

  • 41. Pharmacovigilance in India: how safe are the new drugs? How sure are we?
    Joshi SR; Sapatnekar SM
    J Assoc Physicians India; 2008 Dec; 56():933-4. PubMed ID: 19322970
    [No Abstract]   [Full Text] [Related]  

  • 42. [Evaluation of reports on "pregnancy and drugs" received during a period of 39 months by the Regional Pharmacovigilance Center, Lorraine (Nancy)].
    Hanesse B; Trechot P; el Kouch S; Pierfitte C; Royer R; Netter P
    Therapie; 1995; 50(5):471-2. PubMed ID: 8571291
    [No Abstract]   [Full Text] [Related]  

  • 43. Methods for improving the reporting of adverse effects.
    Prescrire Int; 2011 Mar; 20(114):71. PubMed ID: 21648229
    [No Abstract]   [Full Text] [Related]  

  • 44. [Immunization: adverse event reporting system].
    Weil-Olivier C; Jacquet A
    Arch Pediatr; 2006 Jun; 13(6):646-8. PubMed ID: 16697590
    [No Abstract]   [Full Text] [Related]  

  • 45. Compliance in European pharmacovigilance: a regulatory view.
    Arlett PR; Harrison P
    Pharmacoepidemiol Drug Saf; 2001; 10(4):301-2. PubMed ID: 11760490
    [No Abstract]   [Full Text] [Related]  

  • 46. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Retrospective study of adverse drug reactions in the elderly: experience of regional center for pharmacovigilance].
    Bruneau S; Bruhat C; Lagarce L; Lainé-Cessac P
    Therapie; 2001; 56(6):785-91. PubMed ID: 11878111
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacovigilance in New Zealand: the role of the New Zealand Pharmacovigilance Centre in facilitating safer medicines use.
    Kunac DL; Harrison-Woolrych M; Tatley MV
    N Z Med J; 2008 Oct; 121(1283):76-89. PubMed ID: 18841188
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Systemic adverse drug reactions: a preliminary report from the regional pharmacovigilance center, western Nepal.
    P S; P M; Pr S
    Pak J Pharm Sci; 2008 Oct; 21(4):465-7. PubMed ID: 18930872
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adverse drug reaction monitoring and the Internet: evaluation of the use of the Internet by French Pharmacovigilance Centres and a non-exhaustive survey of websites of interest for collecting information about adverse drug reaction.
    Morel P; Vandel B
    Therapie; 1999; 54(5):525-32. PubMed ID: 10667084
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Improving adverse drug reaction reporting in the community setting.
    McCloskey BA
    Med Interface; 1996 May; 9(5):85-7. PubMed ID: 10157690
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Pharmacovigilance: a case of phantom ships and Russian roulette].
    Stricker BH
    Ned Tijdschr Geneeskd; 2002 Jul; 146(27):1258-61. PubMed ID: 12138668
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biovigilance and pharmacovigilance for haemophilia.
    Weinstein M; Makris M; Ludlam CA
    Haemophilia; 2010 Jul; 16 Suppl 5():17-21. PubMed ID: 20590851
    [No Abstract]   [Full Text] [Related]  

  • 54. 19th French pharmacovigilance meeting. Health professionals and consumers are inadequately informed.
    Prescrire Int; 1998 Dec; 7(38):188-90. PubMed ID: 10848054
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Contribution of the regional drug information center towards drug safety.
    Palaian S; Mishra P; Shankar PR; Bista D; Purwar B
    JNMA J Nepal Med Assoc; 2006; 45(161):216-8. PubMed ID: 17160101
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adverse reactions to anticoagulants and to antiplatelet drugs recorded by the German spontaneous reporting system.
    Tiaden JD; Wenzel E; Berthold HK; Müller-Oerlinghausen B
    Semin Thromb Hemost; 2005; 31(4):371-80. PubMed ID: 16149013
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Early adverse drug event signal detection within population-based health networks using sequential methods: key methodologic considerations.
    Brown JS; Kulldorff M; Petronis KR; Reynolds R; Chan KA; Davis RL; Graham D; Andrade SE; Raebel MA; Herrinton L; Roblin D; Boudreau D; Smith D; Gurwitz JH; Gunter MJ; Platt R
    Pharmacoepidemiol Drug Saf; 2009 Mar; 18(3):226-34. PubMed ID: 19148879
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New drugs: watch out for unexpected adverse effects.
    Prescrire Int; 2002 Oct; 11(61):150-1. PubMed ID: 12378747
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France.
    Olivier P; Montastruc JL
    Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):808-12. PubMed ID: 16700082
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Building a structured monitoring and evaluating system of postmarketing drug use in Shanghai.
    Du W; Levine M; Wang L; Zhang Y; Yi C; Wang H; Wang X; Xie H; Xu J; Jin H; Wang T; Huang G; Wu Y
    Can J Clin Pharmacol; 2007; 14(1):e40-4. PubMed ID: 17237524
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.